Sunshine Biopharma Inc. might be living the concept of being in the right place at the right time. This Canadian company is currently focusing on three product lines—the SBFM-PL4 COVID-19 treatment, the Adva-27a anticancer compound, and the Essential 9 nutritional supplements—and each is moving forward with positive results.
In February, the company successfully closed an $8 million public offering and was uplisted to the Nasdaq Capital Market. Also, in February, the company entered into an agreement with the University of Arizona to further the development of novel PLpro inhibitors used in its anti-cancer compound.
